ERBB2 and neoplasm: To understand the possible significance of these HER2-coexpressed metabolites, their expression was examined in distinct HER2 subgroups and associated with clinical parameters (such as age, sex and tumour stage) and pathological markers (such as P53 and Kiki 67).